SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
VRCA

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$2.74-$0.14 (-5.03%)
 
Market cap
$47.1M
Insider Score
Health Score
Analyst consensus
Listed since
Jun 15, 2018
Market Cap$47.07M-42.0%
Revenue (ttm)$22.89M-25.7%
Net Income-$43.32M-66.5%
EPS-$2.29+33.6%
Shares Out17.18M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume127,031
Open$2.81
Previous Close$2.88
Day's Range$2.73 - $2.98
52-Week Range$2.73 - $9.82
Beta1.67
AnalystsBuy
Price Target$9.00(+228.47%)
Earnings DateMar 10, 2027
-4.68% (1D)
No price history available.

About VRCA

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Address
44 West Gay Street Suite 400, West Chester, PA, 19380, US
Market Cap
47 million
Employees
76
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$18.17M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Distressed
From VRCA’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-5.03%
5 Days
-20.81%
1 Month
-28.46%
6 Months
-54.79%
1 Year
-41.95%

$VRCA stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in VRCA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by VRCA's directors and management

Net Shares Purchased by Insiders−5M−2.5M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

VRCA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New VRCA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to VRCA from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in VRCA

VTIVanguard Morningstar Total Stock Market ETF$571.39K
VXFVanguard Extended Market ETF$453.81K
IWCiShares Micro-Cap ETF$86.71K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from VRCA’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
57.32
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: Q3 2026 earnings coverage emphasizes record YCANTH revenue; multiple earnings-focused headlines suggest strong financial performance and business momentum.

Recent Insider Activity

Buys
12
Sells
0
Buy Value
$18.17M
Distinct Buyers
5

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.